Berenberg Bank analyst Luisa Hector maintained a Buy rating on Merck & Company (MRK – Research Report) yesterday and set a price ...

TIME convened the first-ever TIME100 Health Leadership Forum to bring together individuals driving innovation and creating equitable initiatives within the health sector.

Zacks Research lowered their Q3 2024 earnings estimates for Merck & Co., Inc. in a report issued on Monday, October 21st.

In recent trading, Merck & Co Inc (MRK) stock price has shown some volatility, fluctuating -3.05% over the last five trades and -9.24% over the past 30 trades. This represents a notable shift from ...

The 1) Market is expected to reach a substantial USD 34.83 billion by 2033, according to a new report. This reflects a ...

From 2023 to 2033, Checkpoint Inhibitor Refractory Cancer sales are expected to flourish at a CAGR of 11.26%. By 2033, the ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

A new study has unveiled crucial information about the incidence and risk factors of oral human papillomavirus (HPV) infections among men in the United States, Mexico and Brazil. Moffitt Cancer Center ...

We recently compiled a list of the 8 Best US Stocks For Foreign Investors Right Now. In this article, we are going to take a ...

"Clesrovimab administered as a single dose for infants of all weights provided protection against mild, moderate, and severe ...

Wall Street promptly began trying to weigh the compound’s marketplace odds after Merck & Co. Inc. detailed positive data from the phase IIb/III trial known as MK-1654-004 with clesrovimab, an ...